UniProtKB/Swiss-Prot O95678 : Variant p.Ser485Arg
Keratin, type II cytoskeletal 75
Gene: KRT75
Feedback ?
Variant information
Variant position:
485
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LB/B
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Serine (S) to Arginine (R) at position 485 (S485R, p.Ser485Arg).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Change from small size and polar (S) to large size and basic (R)
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
-1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Polymorphism:
The Thr-161 variant may increase risk to develop pseudofolliculitis barbae (PFB) [MIM:612318 ]. PFB is a common hair disorder characterized by a pustular foreign body inflammatory reaction that is induced by ingrown hairs of the facial and submental (barbea) regions after regular shaving. It occurs predominantly in black males, while it is rather rare and usually far less severe in Caucasian males.
Additional information on the polymorphism described.
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
485
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
551
The length of the canonical sequence.
Location on the sequence:
EGVSPVNISVVTSTLSSGYG
S GSSIGGGNLGLGGGSGYSFT
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human EGVSPVNISVVTSTLSSGYGS GSSIGGGNLGLGGGSGYSFT
Mouse EGVSPVNISVVTSTVSSGYGG GANIGGGSLGLGGNSGYSFT
Rat EGVSPVNISVVTSTVSSGYGG GTNIGGGSLGLGGNSGYSFT
Bovine EGVSPVNISVVTSTVSSGYGG GSSIGSGSLGLSGGSGCSFM
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
1 – 551
Keratin, type II cytoskeletal 75
Region
459 – 551
Tail
Literature citations
A novel human type II cytokeratin, K6hf, specifically expressed in the companion layer of the hair follicle.
Winter H.; Langbein L.; Praetzel S.; Jacobs M.; Rogers M.A.; Leigh I.M.; Tidman N.; Schweizer J.;
J. Invest. Dermatol. 111:955-962(1998)
Cited for: NUCLEOTIDE SEQUENCE [MRNA]; TISSUE SPECIFICITY; VARIANTS GLY-91 AND ARG-485;
Characterization of a 300 kbp region of human DNA containing the type II hair keratin.
Rogers M.A.; Winter H.; Langbein L.; Wolf C.; Schweizer J.;
J. Invest. Dermatol. 114:464-472(2000)
Cited for: NUCLEOTIDE SEQUENCE [MRNA]; VARIANTS GLY-91 AND ARG-485;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.